Reprieve Cardiovascular
Milford
About Reprieve Cardiovascular
Reprieve Cardiovascular is a pioneering medical device company focused on innovative fluid management technologies for congestive heart failure. The company's Reprieve technology is being investigated as an innovative fluid management treatment. Providing clinicians with the ability to precisely control a patient’s fluid volume may both enable improved cardiac care, as well as, be instrumental in the decongestion of acutely decompensated heart failure patients (ADHF). Reprieve Cardiovascular, Inc. and RenalGuard Solutions, Inc. are subsidiaries of parent company CardioRenal Systems, Inc.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $182.9M
- Funding stage: Early Stage Venture
- Last round: Debt Financing (Aug 2025)
- Website: reprievecardio.com
- Phone: [email protected]
Industries & Categories
Health Care, Medical Device, Wellness
Social Profiles
Canonical: https://fsome.com/organization/reprieve-cardiovascular-36963 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.